Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Attention-deficit/hyperactivity disorder (ADHD), one of the most common neuropsychiatric conditions of childhood, often has a chronic course and persists into adulthood in many individuals. ADHD may have a clinically important impact on health-related quality of life in children, a significant impact on parents' emotional health and interfere with family activities/cohesion. To date, the main targets of ADHD treatment have focused on reducing the severity of symptoms during the school day and improving academic performance. However, the treatment of ADHD should reach beyond symptom control to address the issues of social competencies and improvement of health-related quality of life from the perspectives of individuals with ADHD and their families, to support them in reaching their full developmental potential. Methylphenidate (MPH) is recognised as the first-line choice of pharmacotherapy for ADHD in children and adolescents. This paper focuses on the importance and benefits to child development of ADHD symptom control beyond the school day only, i.e. extending into late afternoon and evening and uses the example of an extended-release MPH formulation (OROS((R)) MPH) to demonstrate the potential benefits of active full day coverage (12 h) with a single daily dose. Concerns of long-term stimulant treatment are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.942 · Cited by 5,346
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.5.564 · Cited by 1,738 · cited 2×
“syndrome and borderline personality disorder [12].”
BackgroundMannuzza, S. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820190067007 · Cited by 1,368 · cited 2×
“Such an ADHD treatment option has been shown to improve driving performance and reduce the risk of car accidents [20, 37, 59, 67, 71].”
BackgroundMolina, B. S. G., Hinshaw, S. P., Swanson, J. M., Arnold, L. E., Vitiello, B., Jensen, P. S., Epstein, J. N., Hoza, B., Hechtman, L., Abikoff, H. B., et al. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31819c23d0 · Cited by 1,182 · cited 1×
“not differ significantly on repeated measures or newly analysed variables such as school grades, arrests, psychiatric hospitalisations and other clinically relevant outcomes [64].”
BackgroundADHD Comorbidity Findings From the MTA Study: Comparing Comorbid Subgroups
JENSEN, P. S., HINSHAW, S. P., KRAEMER, H. C., LENORA, N., NEWCORN, J. H., ABIKOFF, H. B., MARCH, J. S., ARNOLD, L. E., CANTWELL, D. P., CONNERS, C. K., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00009 · Cited by 974 · cited 1×
“For example, the MTA study found that stimulant medication was equally effective in reducing ADHD symptoms in patients with and without comorbid anxiety [44, 104].”
ResultWilens, T. E., Faraone, S. V., Biederman, J., & Gunawardene, S. (2003) · Pediatrics · doi:10.1542/peds.111.1.179 · Cited by 872
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830
Clinical correlates of inpatient suicide
Busch, K. A., Fawcett, J., & Jacobs, D. G. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0105 · Cited by 750
Attention deficit hyperactivity disorder adults: Comorbidities and adaptive impairments
Murphy, K., & Barkley, R. A. (1996) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(96)90022-x · Cited by 700 · cited 2×
“Such an ADHD treatment option has been shown to improve driving performance and reduce the risk of car accidents [20, 37, 59, 67, 71].”
BackgroundEuropean clinical guidelines for hyperkinetic disorder ? first upgrade
Taylor, E., D�pfner, M., Sergeant, J., Asherson, P., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Rothenberger, A., Sonuga-Barke, E., et al. (2004) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-004-1002-x · Cited by 682 · cited 8×
“Growth may be impacted with stimulant therapy, and appetite reduction may be seen at the beginning of treatment [ 103 ].”
BackgroundInfluentialSelf-citationKlassen, A. F., Miller, A., & Fine, S. (2004) · Pediatrics · doi:10.1542/peds.2004-0844 · Cited by 565 · cited 1×
“In a survey of 131 children with ADHD, 68.7% of whom had a comorbid psychiatric disorder, the parent version of the child health questionnaire was used to measure physical health, psychosocial health, limitations in family activities and family cohesion [ 50 ].”
MethodInfluentialWolraich, M. L., Greenhill, L. L., Pelham, W., Swanson, J., Wilens, T., Palumbo, D., Atkins, M., McBurnett, K., Bukstein, O., August, G., et al. (2001) · Pediatrics · doi:10.1542/peds.108.4.883 · Cited by 502
Pelham, W. E., Gnagy, E. M., Burrows-Maclean, L., Williams, A., Fabiano, G. A., Morrisey, S. M., Chronis, A. M., Forehand, G. L., Nguyen, C. A., Hoffman, M. T., et al. (2001) · Pediatrics · doi:10.1542/peds.107.6.e105 · Cited by 378
Newcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D., & Atomoxetine/Methylphenidate Comparative Study Group (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05091676 · Cited by 336
ADHD Drugs and Cardiovascular Risk
Nissen, S. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068049 · Cited by 331
Effects of Stimulant Medication on Growth Rates Across 3 Years in the MTA Follow-up
SWANSON, J. M., ELLIOTT, G. R., GREENHILL, L. L., WIGAL, T., ARNOLD, L. E., VITIELLO, B., HECHTMAN, L., EPSTEIN, J. N., PELHAM, W. E., ABIKOFF, H. B., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3180686d7e · Cited by 323 · cited 2×
“However, the effect of stimulant therapy on growth remains a matter of some debate, particularly given the results of a recent analysis that evaluated effects of stimulant medication on growth rates in the follow-up phase of the MTA study [101].”
BackgroundResultEffect of Anxiety on Cognition, Behavior, and Stimulant Response in ADHD
PLISZKA, S. R. (1989) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-198911000-00012 · Cited by 293 · cited 1×
“Similarly, a short-term, fixed-dose investigation, conducted in 43 children with ADHD, found that subjects with comorbid anxiety had a significantly poorer response to MPH than those without anxiety [80].”
BackgroundKRATOCHVIL, C. J., HEILIGENSTEIN, J. H., DITTMANN, R., SPENCER, T. J., BIEDERMAN, J., WERNICKE, J., NEWCORN, J. H., CASAT, C., MILTON, D., & MICHELSON, D. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200207000-00008 · Cited by 292 · cited 2×
“Safety and tolerability were also similar between the two agents [ 52 ].”
BackgroundResultEffect of Stimulants on Height and Weight: A Review of the Literature
Faraone, S. V., Biederman, J., Morley, C. P., & Spencer, T. J. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.obo13e31817eoea7 · Cited by 286
Becker, A., Hagenberg, N., Roessner, V., Woerner, W., & Rothenberger, A. (2004) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-004-2004-4 · Cited by 269
GREENHILL, L. L., HALPERIN, J. M., & ABIKOFF, H. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199905000-00011 · Cited by 268
Mannuzza, S., Klein, R. G., Truong, N. L., Moulton, J. L., Roizen, E. R., Howell, K. H., & Castellanos, F. X. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07091465 · Cited by 263 · cited 3×
“The authors conclude that initiation of MPH treatment at an early age does not increase the risk of later substance abuse and may, in fact, have beneficial long-term effects [60].”
BackgroundInfluentialMOLINA, B. S. G., FLORY, K., HINSHAW, S. P., GREINER, A. R., ARNOLD, L. E., SWANSON, J. M., HECHTMAN, L., JENSEN, P. S., VITIELLO, B., HOZA, B., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3180686d96 · Cited by 255 · cited 1×
“001), suggesting that the cause-and-effect relationships between treatment for ADHD and delinquency are unclear [63].”
BackgroundSwanson, J., Gupta, S., Lam, A., Shoulson, I., Lerner, M., Modi, N., Lindemulder, E., & Wigal, S. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.2.204 · Cited by 248
Biederman, J., Monuteaux, M. C., Spencer, T., Wilens, T. E., MacPherson, H. A., & Faraone, S. V. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07091486 · Cited by 239 · cited 1×
“However, a recent prospective, follow-up study, in which 112 children with ADHD were examined at baseline and again after 10 years of follow up, did not replicate these findings, instead demonstrating that stimulant treatment during childhood and adolescence neither increased nor decreased the risk for subsequent subs…”
BackgroundAttention deficit hyperactivity disorder and suicide: a review of possible associations
James, A., Lai, F. H., & Dahl, C. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00384.x · Cited by 224 · cited 2×
“Several studies have shown a possible association between ADHD and suicide [43, 46].”
BackgroundSwanson, J., Gupta, S., Guinta, D., Flynn, D., Agler, D., Lerner, M., Williams, L., Shoulson, I., & Wigal, S. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70038-x · Cited by 216 · cited 2×
“and troughs in plasma concentrations, which might lead to ‘waxing and waning’ of behavioural symptom improvement throughout the day and, potentially, to rebound [98].”
BackgroundHECHTMAN, L., ABIKOFF, H., KLEIN, R. G., WEISS, G., RESPITZ, C., KOURI, J., BLUM, C., GREENFIELD, B., ETCOVITCH, J., FLEISS, K., et al. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000128796.84202.eb · Cited by 197 · cited 1×
“Other benefits include improvements in working memory, persistence of effort, academic productivity, accuracy and handwriting [5, 38].”
BackgroundChan, E., Zhan, C., & Homer, C. J. (2002) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.156.5.504 · Cited by 183 · cited 1×
“Although the individuals with ADHD and their families are of primary concern, the benefits of treatment may also extend to the utilisation and cost of health care resources; in the US these are significantly greater for children and adolescents with ADHD than for people without ADHD, making treatment cost-effective re…”
BackgroundBARKLEY, R. A. (2004) · Journal of Psychiatric Practice · doi:10.1097/00131746-200401000-00005 · Cited by 165
Swanson, J. (2003) · CNS Drugs · doi:10.2165/00023210-200317020-00004 · Cited by 162
Cardiovascular Monitoring and Stimulant Drugs for Attention-Deficit/Hyperactivity Disorder
Perrin, J. M., Friedman, R. A., Knilans, T. K., the Black Box Working Group, & Surgery, T. S. O. C. A. C. (2008) · Pediatrics · doi:10.1542/peds.2008-1573 · Cited by 161
Wilens, T. E., McBurnett, K., Bukstein, O., McGough, J., Greenhill, L., Lerner, M., Stein, M. A., Conners, C. K., Duby, J., Newcorn, J., et al. (2006) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.160.1.82 · Cited by 160
Gau, S. S. F., Shen, H.-Y., Chou, M.-C., Tang, C.-S., Chiu, Y.-N., & Gau, C.-S. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.286 · Cited by 148 · cited 2×
“The requirement for multiple daily dosing of MPH increases the likelihood of poor adherence, particularly in adolescents, and poor persistence with therapy has been shown to be associated with increased maternal psychological distress, indifferent parenting, maternal overprotection/control, poor family support, decrea…”
BackgroundWILENS, T., PELHAM, W., STEIN, M., CONNERS, C. K., ABIKOFF, H., ATKINS, M., AUGUST, G., GREENHILL, L., MCBURNETT, K., PALUMBO, D., et al. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000046814.95464.7d · Cited by 148
Slowing of growth in height and weight on stimulants: A characteristic pattern
Poulton, A., & Cowell, C. (2003) · Journal of Paediatrics and Child Health · doi:10.1046/j.1440-1754.2003.00107.x · Cited by 132 · cited 2×
“Indeed, results from a retrospective review of growth data from files of all newly treated patients with ADHD in one paediatric practice, reported that during the first 6 months on stimulant medication, 86% of children had a height velocity below the age-corrected mean and there was weight loss in 76% of children [82].”
BackgroundResponse to Methylphenidate in Children With ADHD and Comorbid Anxiety
DIAMOND, I. R., TANNOCK, R., & SCHACHAR, R. J. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199904000-00012 · Cited by 132
Does Prolonged Therapy With a Long-Acting Stimulant Suppress Growth in Children With ADHD?
SPENCER, T. J., FARAONE, S. V., BIEDERMAN, J., LERNER, M., COOPER, K. M., & ZIMMERMAN, B. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000205710.01690.d4 · Cited by 125 · cited 1×
“Clinically insignificant effects on height and weight (0.23 cm and 1.23 kg, respectively, in 21 months) have been reported in another trial, with no associated benefit from drug holidays [ 91 ].”
ResultInfluentialPsychiatric disorders and attempted suicide among adolescents with substance use disorders
Kelly, T. M., Cornelius, J. R., & Clark, D. B. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2003.10.004 · Cited by 123
Cox, D. J., Merkel, R. L., Penberthy, J. K., Kovatchev, B., & Hankin, C. S. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200403000-00007 · Cited by 120
Kemner, J. E., Starr, H. L., Ciccone, P. E., Hooper-Wood, C. G., & Crockett, R. S. (2005) · Advances in Therapy · doi:10.1007/bf02849870 · Cited by 99 · cited 3×
“[48] performed a large, community-based, open-label study to evaluate treatment outcomes in children (aged 6–12 years) with ADHD, randomized to either once-daily OROS MPH (n = 850) or atomoxetine (n = 473) for 3 weeks.”
BackgroundMethodResultInfluentialCox, D. J., Humphrey, J. W., Merkel, R. L., Penberthy, J. K., & Kovatchev, B. (2004) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.17.4.235 · Cited by 97 · cited 2×
“Moreover, compared with non-affected children and adolescents, those with ADHD are at higher risk of sustaining accidental injuries, and requiring emergency department visits and hospitalisations [20, 41].”
BackgroundCox, D. J., Merkel, R. L., Moore, M., Thorndike, F., Muller, C., & Kovatchev, B. (2006) · PEDIATRICS · doi:10.1542/peds.2005-2947 · Cited by 95 · cited 2×
“In terms of overall driving performance, OROS MPH was significantly superior to placebo, whereas MAS XR was not associated with better driving than placebo [ 21 ].”
BackgroundDoes Childhood Treatment of ADHD With Stimulant Medication Affect Substance Abuse in Adulthood?
Volkow, N. D., & Swanson, J. M. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020237 · Cited by 85 · cited 2×
“There is concern that the use of stimulant medications to treat ADHD may play a role in the development of drug addiction [111].”
BackgroundWang, Y., Zheng, Y., Du, Y., Song, D. H., Shin, Y.-J., Cho, S. C., Kim, B. N., Ahn, D. H., Marquez-Caraveo, M. E., Gao, H., et al. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670601057767 · Cited by 84 · cited 2×
“001) [112].”
BackgroundGarland, E. J. (1998) · Journal of Psychopharmacology · doi:10.1177/026988119801200410 · Cited by 77 · cited 1×
“One of the major challenges of MPH treatment is ‘wearingoff’ or rebound effects [31].”
BackgroundEmergence of Tics in Children with ADHD: Impact of Once-Daily OROS® Methylphenidate Therapy
Palumbo, D., Spencer, T., Lynch, J., Co-Chien, H., & Faraone, S. V. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/1044546041649138 · Cited by 67 · cited 1×
“Although the risk of tic episodes was higher in patients with a history of tics than in those with no history of tics, data suggested that OROS MPH does not significantly induce or exacerbate tics in children with ADHD [76].”
Buitelaar, J. K., Wilens, T. E., Zhang, S., Ning, Y., & Feldman, P. D. (2009) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2008.01960.x · Cited by 41 · cited 2×
“Correlation analysis revealed a moderate-tostrong association between changes in the LPS total versus ADHDRS-IV-Parent:Inv total (r =- 6.8) [ 14 ].”
BackgroundInfluentialSelf-citationChou, W., Chou, M., Tzang, R., Hsu, Y., Gau, S. S., Chen, S., Wu, Y., Huang, Y., Liang, H., & Cheng, H. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.01937.x · Cited by 36
Kim, Y., Shin, M., Kim, J., Yoo, H., Cho, S., & Kim, B. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1010 · Cited by 25 · cited 1×
“Recent evidence from a 28-day, open-label trial suggests that behavioural improvements observed when children with ADHD are switched from IR MPH to OROS MPH may also be accompanied by improvements in neurocognitive function, although these findings have yet to be replicated in large-scale, controlled trials [49].”
Background
Cited by
Attention‐deficit hyperactivity disorder ( ADHD ): an updated review of the essential facts
Tarver, J., Daley, D., & Sayal, K. (2014) · Child: Care, Health and Development · doi:10.1111/cch.12139 · Cited by 234
Lange, M., Norton, W., Coolen, M., Chaminade, M., Merker, S., Proft, F., Schmitt, A., Vernier, P., Lesch, K.-P., & Bally-Cuif, L. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.29 · Cited by 175
Jin, W., Du, Y., Zhong, X., & David, C. (2014) · Asia-Pacific Psychiatry · doi:10.1111/appy.12114 · Cited by 36
“In addition, it may have clinically important effects on the health-related quality of life in children, the emotional health of parents, and the activities/ cohesion of families (Buitelaar, 2010).”
BackgroundWeiss, M., Childress, A., Mattingly, G., Nordbrock, E., Kupper, R. J., & Adjei, A. L. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0166 · Cited by 30
“Functional impairment encompasses the inability to complete tasks at school or at home, has a substantial impact on a child’s or adolescent’s ability to have meaningful friendships, and can have a negative impact on family relationships (Buitelaar and Medori 2010).”
Background
Metadata
- Authors
- Buitelaar, J., & Medori, R.
- Venue
- European Child & Adolescent Psychiatry
- Published
- 2009-10-13
- Volume
- 19
- Issue
- 4
- Pages
- 325-340
- ISSN
- 1018-8827 (ISSN-L)
- 1435-165X
- OpenAlex
- W2160305158
- Cited by
- 80
- References
- 52
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.